Investments and Forward Contracts	3 Months Ended
Oct. 03, 2026
Investments, Debt and Equity Securities [Abstract]
Investments and Forward Contracts	Note 7. Investments and Forward Contracts Short-Term Investments As of October 3, 2026, the Company’s short-term investments of $2.1 million were primarily related to the deferred compensation plan and were invested in equity securities. As of June 27, 2026, the Company’s short-term investments of $2.0 million were primarily related to the deferred compensation plan and were invested in equity securities. Trading securities are reported at fair value, with unrealized gains or losses resulting from changes in fair value recognized in the Consolidated Statements of Operations as a component of Interest and other income, net. Strategic Investment During fiscal 2025, the Company invested $3.0 million in a non-marketable equity security in a privately held company. The investment is included in Other non-current assets on the Consolidated Balance Sheets and is classified as Level 3 within the fair value hierarchy. This investment is carried at cost and because the investment does not have a readily determinable fair value it will be adjusted for changes resulting from observable price changes under the Measurement Alternative methodology. There were no impairments or adjustments to the carrying value for the three months ended October 3, 2026. Equity Investment The Company acquired an equity interest in Sensorsan Sensor Teknolojileri Anonim Sirketi (Sensorsan), a privately held entity and owns 40 percent of Sensorsan, through its acquisition of Inertial Labs. The Company accounts for its investment in Sensorsan under the equity method of accounting. Under the equity method, the carrying value of the Company's investment is adjusted for its proportionate share of Sensorsan's net income or loss and the elimination of unrealized profits on transactions with Sensorsan, as applicable. The Company recognized equity method earnings related to its investment in Sensorsan of $1.6 million for the three months ended October 3, 2026 and a net loss of $0.1 million for the three months ended September 27, 2025. As of October 3, 2026 and June 27, 2026, the carrying value of the Company’s investment in Sensorsan was $3.6 million and $2.0 million, respectively, and was included in Other non-current assets on the Consolidated Balance Sheets. The Company sells certain products to Sensorsan. During the three months ended October 3, 2026 and September 27, 2025, revenue from sales to Sensorsan was $5.4 million and $0.4 million, respectively. Non-Designated Foreign Currency Forward Contracts The Company has foreign subsidiaries that operate and sell the Company’s products in various markets around the world. As a result, the Company is exposed to foreign exchange risks. The Company utilizes foreign exchange forward contracts to manage foreign currency risk associated with foreign currency denominated monetary assets and liabilities, primarily certain short-term intercompany receivables and payables, and to reduce the volatility of earnings and cash flows related to foreign currency transactions. The Company does not use these foreign currency forward contracts for trading purposes. As of October 3, 2026, the Company had forward contracts that were effectively closed but not settled with the counterparties as of the balance sheet date. Therefore, the fair value of these contracts of $1.1 million and $1.7 million is reflected as Prepayments and other current assets and Other current liabilities on the Consolidated Balance Sheets, respectively. As of June 27, 2026, the fair value of these contracts of $1.6 million and $2.5 million is reflected as Prepayments and other current assets and Other current liabilities on the Consolidated Balance Sheets, respectively. The forward contracts outstanding and not effectively closed, with a term of less than 120 days, were transacted near quarter end; therefore, the fair value of the contracts is not significant. As of October 3, 2026 and June 27, 2026, the notional amounts of the forward contracts that the Company held to purchase foreign currencies were $63.4 million and $66.2 million, respectively, and the notional amounts of forward contracts that the Company held to sell foreign currencies were $39.3 million and $38.9 million, respectively. The change in the fair value of these foreign currency forward contracts is recorded as gain or loss in the Consolidated Statements of Operations as a component of Interest and other income, net. The cash flows related to the settlement of foreign currency forward contracts are classified as operating activities. The foreign exchange forward contracts incurred losses of $0.6 million and $0.2 million for the three months ended October 3, 2026 and September 27, 2025, respectively.

As of October 3, 2026, the Company’s short-term investments of $2.1 million were primarily related to the deferred compensation plan and were invested in equity securities.

As of June 27, 2026, the Company’s short-term investments of $2.0 million were primarily related to the deferred compensation plan and were invested in equity securities.

Trading securities are reported at fair value, with unrealized gains or losses resulting from changes in fair value recognized in the Consolidated Statements of Operations as a component of Interest and other income, net.

During fiscal 2025, the Company invested $3.0 million in a non-marketable equity security in a privately held company. The investment is included in Other non-current assets on the Consolidated Balance Sheets and is classified as Level 3 within the fair value hierarchy.

This investment is carried at cost and because the investment does not have a readily determinable fair value it will be adjusted for changes resulting from observable price changes under the Measurement Alternative methodology. There were no impairments or adjustments to the carrying value for the three months ended October 3, 2026.

The Company acquired an equity interest in Sensorsan Sensor Teknolojileri Anonim Sirketi (Sensorsan), a privately held entity and owns 40 percent of Sensorsan, through its acquisition of Inertial Labs.

The Company accounts for its investment in Sensorsan under the equity method of accounting. Under the equity method, the carrying value of the Company's investment is adjusted for its proportionate share of Sensorsan's net income or loss and the elimination of unrealized profits on transactions with Sensorsan, as applicable.

The Company recognized equity method earnings related to its investment in Sensorsan of $1.6 million for the three months ended October 3, 2026 and a net loss of $0.1 million for the three months ended September 27, 2025. As of October 3, 2026 and June 27, 2026, the carrying value of the Company’s investment in Sensorsan was $3.6 million and $2.0 million, respectively, and was included in Other non-current assets on the Consolidated Balance Sheets. The Company sells certain products to Sensorsan. During the three months ended October 3, 2026 and September 27, 2025, revenue from sales to Sensorsan was $5.4 million and $0.4 million, respectively.

The Company has foreign subsidiaries that operate and sell the Company’s products in various markets around the world. As a result, the Company is exposed to foreign exchange risks. The Company utilizes foreign exchange forward contracts to manage foreign currency risk associated with foreign currency denominated monetary assets and liabilities, primarily certain short-term intercompany receivables and payables, and to reduce the volatility of earnings and cash flows related to foreign currency transactions. The Company does not use these foreign currency forward contracts for trading purposes.

As of October 3, 2026, the Company had forward contracts that were effectively closed but not settled with the counterparties as of the balance sheet date. Therefore, the fair value of these contracts of $1.1 million and $1.7 million is reflected as Prepayments and other current assets and Other current liabilities on the Consolidated Balance Sheets, respectively. As of June 27, 2026, the fair value of these contracts of $1.6 million and $2.5 million is reflected as Prepayments and other current assets and Other current liabilities on the Consolidated Balance Sheets, respectively.

The forward contracts outstanding and not effectively closed, with a term of less than 120 days, were transacted near quarter end; therefore, the fair value of the contracts is not significant. As of October 3, 2026 and June 27, 2026, the notional amounts of the forward contracts that the Company held to purchase foreign currencies were $63.4 million and $66.2 million, respectively, and the notional amounts of forward contracts that the Company held to sell foreign currencies were $39.3 million and $38.9 million, respectively.

The change in the fair value of these foreign currency forward contracts is recorded as gain or loss in the Consolidated Statements of Operations as a component of Interest and other income, net. The cash flows related to the settlement of foreign currency forward contracts are classified as operating activities. The foreign exchange forward contracts incurred losses of $0.6 million and $0.2 million for the three months ended October 3, 2026 and September 27, 2025, respectively.